Reino Unido

Professor Ian Chau holds the position of consultant medical oncologist within the
Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and Professor at the
Institute of Cancer Research, London & Surrey, UK. He qualified from the United
Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London,
before undergoing medical oncology specialist training and clinical research fellowship at
the Royal Marsden Hospital. He is the chief or principal investigator of multiple phase I,
II and III clinical trials evaluating novel treatment strategies and agents in various cancer
signalling pathways. He serves or has served on American Society of Clinical Oncology
(ASCO) Scientific Program Committee, ASCO Education Committee, European Society
of Medical Oncology (ESMO) Congress Steering Committee, ESMO Asia Scientific
Programme and Steering Committee, ESMO Educational Committee, Japanese Society
of Medical Oncology (JSMO) International Steering Committee and UK National Cancer
Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study
Groups, He was the track leaders for Gastrointestinal Cancer for ASCO Annual Meeting
Education Committee, ESMO Scientific Committee, Scientific Chairman for ESMO Asia
Congress and ASCO GI Symposium 2022 & 2023. He is on the Trial Management
Groups and Trial Steering Groups of multiple national and global phase II-III
gastrointestinal cancer and lymphoma trials. He serves or has served on the UK National
Institute of Health and Care Excellence (NICE) Clinical Guideline Development Group
for non-Hodgkin’s Lymphoma, ASCO Expert Panel for the Management of
Immunotherapy Toxicities Guideline and ESMO Clinical Practice Guidelines for
Hepatocellular Carcinoma panel. He is the recipient of Swedish Society of GI Oncology
Bengt Glimelius Award 2016, merit awards from ASCO Gastrointestinal Cancer
Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize,
fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical
Cancer Research Workshop. He has given invited lectures in over 30 countries. He has
served on international drug development advisory boards and has peer review
publications in the New England Journal of Medicine, The Lancet, The Lancet Oncology,
Journal of Clinical Oncology and other leading oncology / biomedical journals.